The planned program is part of beta test of Repositive’s Cancer Models platform which connects biopharmaceutical companies and contract research organizations.
Vertex Pharmaceuticals has invested £10.5 million in the British analytics company as the companies launch a multiyear R&D partnership seeking novel drug targets.
LabCorp will be able to develop and commercialize the test for patients with an elevated PSA to determine their risk of having clinically significant prostate cancer.
Using the method, the researchers predicted the effects of over 140 million mutations in different tissues and identified mutations possibly associated with increased risk of several immune diseases.
The firm anticipates that the award will accelerate the development of its over-the-counter and professional-use influenza and multiplex respiratory pathogen tests.
An RNA test in development that confirms whether a patient has HCV within 40 minutes could enable diagnosis and prescribing treatment during a single office visit.
The assay detects a mutation that can confer hearing loss in patients, particularly neonates, who have taken gentamicin, an antibiotic prescribed for certain bacterial infections.
The company will work with medical faculties of the universities of Greifswald and Rostock to develop Dx tools for personalized, immune-based treatments.
